A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse.
Benjamin M GreenbergJames D BowenEnrique AlvarezMoses RodriguezAnthony O CaggianoArthur E WarringtonPing ZhaoAndrew EisenPublished in: Multiple sclerosis journal - experimental, translational and clinical (2022)
: NCT02398461 https://clinicaltrials.gov/ct2/show/study/NCT02398461?term=M22&draw=2&rank=8.